Results 21 to 30 of about 5,803 (182)
The Saudi Journal of Gastroenterology, 2019 Background/Aims: Ledipasvir/sofosbuvir (LDV/SOF) combination is administered for 12 to 24 weeks to treat hepatitis C virus (HCV); guidelines recommend 8 weeks treatment duration for HCV genotype (GT) 1 infection based on the patient's baseline ...
Mohammed A Babatin +8 more
doaj +1 more source
Archives of Medical Science, 2019 Introduction Non-cirrhotic treatment-naive hepatitis C patients infected with genotype 1 can be treated with ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks, but in practice this regimen is frequently extended up to 12 weeks at least in part due to ...
Dorota Zarębska-Michaluk +26 more
doaj +1 more source
The Turkish Journal of Gastroenterology, 2021 Background: In this study, we aimed to investigate the efficacy and safety of sofosbuvir-based therapies in the treatment of chronic hepatitis C in real-world clinical practice. Methods: Data from patients with chronic hepatitis C treated with SOF/LDV ±
Neşe Demirtürk +40 more
doaj +1 more source
Future Journal of Pharmaceutical Sciences, 2018 Objective: A simple, specific, accurate and economic reverse phase liquid chromatographic method was developed for the simultaneous estimation of Sofosbuvir and Ledipasvir in bulk and tablet dosage form.
S.K. Mastanamma +3 more
doaj +1 more source
, 2023 Ultra-performance liquid chromatographic (UPLC) method, for ledipasvir and sofosbuvir determination in bulk mixtures, and in tablets was developed and validated.
D Gowri Sankar, K Pushpa Kumari
core +2 more sources
Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. [PDF]
PLoS ONE, 2016 BACKGROUND:Little is known on the cost-effectiveness of novel regimens for hepatitis C virus (HCV) compared with standard-of-care with pegylated interferon (pegIFN) and ribavirin (RBV) therapy in developing countries.
Guo-Feng Chen +34 more
doaj +1 more source
Balkan Medical Journal, 2023 Background: Treatment using direct-acting antivirals provides high rates of sustained virologic response and a favorable safety profile for patients with chronic hepatitis C virus infection.
Ayşe Serra Artan +13 more
doaj +1 more source
Multivariate Chemometric Models and Application of Genetic Algorithm for Simultaneous Determination of Ledipasvir and Sofosbuvir in Pure Form and in Pharmaceutical Preparation; A Comparative Study [PDF]
Journal of Advanced Pharmacy Research, 2017 Objectives: Four multivariate chemometric methods have been developed for simultaneous determination of sofosbuvir and ledipasvir in their pure and pharmaceutical dosage forms.
Fathy Salama +4 more
doaj +1 more source
Viruses, 2015 Hepatitis C virus (HCV) infection is one of the leading causes of end-stage liver disease and the main indication for liver transplantation (LT) in most countries.
Bruno Roche +3 more
doaj +1 more source
The Turkish Journal of Gastroenterology, 2022 Background: The course of hepatitis C disease has changed with the use of direct-acting antiviral drugs in the treatment of the disease. The aim of this study was to evaluate the real-life efficacy and safety of the sofosbuvir/ledipasvir drug regimen in
Arif Mansur Coşar, Serdar Durak
doaj +1 more source